WIDEX Pure Sound Technology: New New Breakthrough Technology Reproduces Natural Sound in Hearing Aids

What To Know

  • Studies have shown that a processing delay of that length can adversely affect sound quality, especially if processed sound and unprocessed sound mix in the ear canal of a hearing aid user, creating what is called a comb filter effect.
  • Widex PureSound technology, available for the first time in its new flagship WIDEX MOMENT™ hearing aids, features two distinct signal processing pathways — a “classic” version and a new ZeroDelay™ Accelerator pathway that dramatically changes how hearing aids sound.

February 2, 2021

Widex PureSound technology, available for the first time in its new flagship WIDEX MOMENT™ hearing aids, features two distinct signal processing pathways — a “classic” version and a new ZeroDelay™ Accelerator pathway that dramatically changes how hearing aids sound.

“Sound quality and the ‘naturalness’ of sound remain among the most-cited reasons people don’t pursue hearing assistance, despite the great strides in hearing aid innovation made over the last decades,” said Widex Head of Audiology Lise Henningsen. “When hearing aids went digital, drastic improvements in noise reduction and advanced signal processing came at a price, but Widex has figured out how to overcome it.”

Taking an analog sound wave, converting it to a digital signal, processing it, then re-converting into a sound wave takes anywhere from 4 to 8 milliseconds. Studies have shown that a processing delay of that length can adversely affect sound quality, especially if processed sound and unprocessed sound mix in the ear canal of a hearing aid user, creating what is called a comb filter effect.

“When that happens, the perceived quality of the user’s own voice becomes tinny and artificial,” Henningsen said. “Environmental sounds come out distorted and unusual and, overall, the resulting sound becomes strenuous to listen to over time.”

The new Widex ZeroDelay Accelerator reduces the processing delay in WIDEX MOMENT hearing aids to below 0.5 milliseconds — a remarkable technological feat considering Widex already leads the industry with the lowest system delay through its “classic” processing pathway. The company’s unique, legacy time domain filter bank, 32kHz sampling rate, and 16kHz digital bandwidth create very high-fidelity sound across its family of hearing aids, with a processing delay under 3 milliseconds.

For the second, accelerated pathway in Widex PureSound-based hearing aids, signal processing is adapted to the ZeroDelay design to deliver the purest sound quality. Core functions, such as acoustics stability, adaptive gain control, and enhanced signal-to-noise ratio, continue to take priority, while others are modified for the faster ZeroDelay pathway. The two pathways — ZeroDelay and “classic” — exist side-by-side on the Widex PureSound platform. Depending on the needs of the wearer, a hearing care professional can program one or the other as the default mode. From there, the PureSound platform is adaptable to each user’s situation and preferred hearing experience.

“The wearer of hearing aids with the two distinct pathways can switch between them based on where they are and what they want to hear, thereby enjoying far greater sound quality and a more natural experience in most situations,” said Henningsen. Other information here.

SourceWIDEX
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy